NCT04215406

Brief Summary

This research evaluates the effects of maternal exposure to air pollution during pregnancy on adverse pregnancy outcomes, the general demographic information, the level of maternal exposure to air pollution, pregnancy-related information, the occurrence of adverse pregnancy outcomes, and serum indicators of pregnant women during pregnancy are collected. Finally, the research explores that whether the inflammatory cytokine and hormone can mediate the occurrence of adverse pregnancy outcomes under the maternal exposure to air pollution during pregnancy.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
288

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2020

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 25, 2019

Completed
7 days until next milestone

Study Start

First participant enrolled

January 1, 2020

Completed
1 day until next milestone

First Posted

Study publicly available on registry

January 2, 2020

Completed
3.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2023

Completed
Last Updated

April 29, 2022

Status Verified

August 1, 2021

Enrollment Period

3.5 years

First QC Date

December 25, 2019

Last Update Submit

April 27, 2022

Conditions

Keywords

pregnancyair pollutioninflammatory cytokinehormoneeffect

Outcome Measures

Primary Outcomes (1)

  • The occurrence of adverse pregnancy outcomes or delivery

    Adverse pregnancy outcomes including abortion, gestational diabetes mellitus (GDM), hypertensive disorder complicating pregnancy, preterm birth, birth defects and low birth weight(LBW).

    ①For abortion, up to 24 weeks. ②For participants without abortion will be assessed when hypertension disorders of pregnancy and GDM occur, then assessment of preterm birth, LBW and birth defects will be conducted when delivery, up to about 9 months

Study Arms (1)

The level of maternal air pollution exposure during pregnancy

The groups will be decided according to the level of maternal exposure to air pollution during pregnancy. Participants will be divided into experimental group (high level of maternal air pollution exposure) and control group (low level of maternal air pollution exposure) or other groups according to research and actual demand.

Other: The level of air pollution

Interventions

The intervention measure is the level of air pollution, it is a non-human interventional measure based on the weighted average of various air pollutants monitored by air pollution monitoring stations during different period of pregnancy.

The level of maternal air pollution exposure during pregnancy

Eligibility Criteria

Age20 Years - 40 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

The study participants are healthy pregnant women within 6 weeks of pregnancy from the First Affiliated Hospital of Xi'an Jiaotong University, who meet the inclusion and exclusion criteria, and sign the informed consent before the implementation of this research. All the participants will be followed up about 9 months and measured the serum concentration of inflammatory cytokine and hormone.

You may qualify if:

  • The Pregnant women within 6 weeks of gestation from the First Affiliated Hospital of Xi'an Jiaotong University;
  • This pregnancy is natural conception, the last menstrual period is definite and the menstrual cycle is basically regular;
  • The pregnant examinations are performed in our hospital;
  • The pregnant women volunteer to participate in this study and sign the informed consent.

You may not qualify if:

  • The couples have chromosomal abnormalities or hereditary diseases;
  • The pregnant women have trophoblastic diseases such as hydatidiform mole;
  • The pregnant women with genital malformations, such as mediastinal uterus, single-horned uterus, double uterus, etc;
  • The pregnant women are definitively diagnosed with uterine fibroids, ovarian cysts, polycystic ovary syndrome, gynecological inflammation and other gynecological diseases;
  • The pregnant women are definitively diagnosed with hypertensive, diabetes and other chronic disease before pregnancy;
  • The pregnant women are definitively diagnosed with autoimmune diseases such as systemic lupus erythematosus, multiple arteriolar inflammation, rheumatoid arthritis, etc;
  • The participants have other serious diseases.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

First Affiliated Hospital of Xi'an Jiaotong University

Xi'an, Shaanxi, 710000, China

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

The venous blood from pregnant women is acquired in different time point for measurement of serum concentration of inflammatory cytokine and hormone.

Study Officials

  • Wenfang Yang, PHD

    First Affiliated Hospital Xi'an Jiaotong University

    STUDY DIRECTOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 25, 2019

First Posted

January 2, 2020

Study Start

January 1, 2020

Primary Completion

June 30, 2023

Study Completion

June 30, 2023

Last Updated

April 29, 2022

Record last verified: 2021-08

Data Sharing

IPD Sharing
Will not share

Locations